Sionna Therapeutics (SION) Q3 2026 earnings summary

Executive summary

• Development focus shifted to SION-451 + SION-2222 after SION-719 missed its Phase 2a activity endpoint; Phase 2 proof-of-concept trial planned for Q1 2027.

• Cash, cash equivalents and marketable securities totaled $249.8 million at September 30, 2026, with runway projected into H2 2029 under current plans.

Financial highlights

• Q3 2026 operating expenses were $34.8 million versus $23.8 million in Q3 2025; net loss was $32.4 million versus $20.3 million.

• Q3 2026 R&D expense was $22.0 million versus $16.0 million; G&A expense was $12.8 million versus $7.8 million.

• 9M 2026 operating expenses were $96.9 million versus $65.4 million; net loss was $89.1 million versus $54.8 million.

• No product-sales revenue has been generated; Q3 2026 interest income was $2.4 million versus $3.5 million, reflecting lower average cash and investment balances.

• Net loss included $6.2 million of restructuring charges in Q3 and 9M 2026: $5.8 million cash-related and $0.4 million non-cash stock compensation.

Outlook and guidance

• AscenSION CF is planned to initiate in Q1 2027 as an open-label, 28-day trial in people with CF switching from Trikafta to SION-451 + SION-2222.

• Assessments include sweat chloride, safety and PK; the trial will incorporate learnings on dosing adherence and sweat chloride variability from PreciSION CF.

• Existing cash, cash equivalents and marketable securities are expected to fund operations into H2 2029 under current plans; substantial additional capital will be required.

• Near-term operating expenses and losses are expected to decrease after restructuring, but expenses may rise as candidates advance to later-stage development.